Compare AIRG & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIRG | TLPH |
|---|---|---|
| Founded | 1995 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.5M | 70.3M |
| IPO Year | 2016 | 2010 |
| Metric | AIRG | TLPH |
|---|---|---|
| Price | $5.86 | $1.34 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $6.25 | N/A |
| AVG Volume (30 Days) | 74.4K | ★ 396.0K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.65 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $51,779,000.00 | $2,151,000.00 |
| Revenue This Year | $10.31 | N/A |
| Revenue Next Year | $20.71 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.00 | $0.39 |
| 52 Week High | $7.66 | $1.57 |
| Indicator | AIRG | TLPH |
|---|---|---|
| Relative Strength Index (RSI) | 40.39 | 56.90 |
| Support Level | $3.82 | $0.74 |
| Resistance Level | $6.34 | $1.45 |
| Average True Range (ATR) | 0.25 | 0.09 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 29.41 | 44.00 |
Airgain Incs a provider of advance wireless connectivity solutions. It is focused on delivering high-performance, cost-effective, and energy-efficient wireless solutions that enable rapid market deployment. It mission is to connect the world through integrated, and optimized wireless solutions. Companies' diverse product portfolio serves three primary markets: enterprise, automotive, and consumer. While historically recognized for high-performance radio frequency (RF) components, Airgain is increasingly delivering integrated, system-level connectivity solutions that combine hardware, software, and cloud management. The enterprise market demands reliable wireless access across diverse settings, including smart cities, campuses, stadiums, transportation hubs, utilities, buildings suburbs.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.